Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

NCT00365222 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped IRB Study Closure

Conditions

Glioblastoma
Gliosarcoma

Interventions

DRUG: Temozolomide

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]